USEUROPEAFRICAASIA 中文雙語Fran?ais
    Home / World

    Novartis loses landmark patent case

    By Agencies in New Delhi | China Daily | Updated: 2013-04-02 07:47

     Novartis loses landmark patent case

    Tanmay, 4, who has cancer, leaves after getting treatment at Tata cancer hospital in Mumbai, India, on Monday. India's Supreme Court rejected drug maker Novartis AG's attempt to patent a new version of the cancer drug Glivec. Rafiq Maqbool / Associated Press

    India's Supreme Court rejected a patent bid by Swiss drug giant Novartis on Monday in a landmark ruling activists say will protect access to cheap generic drugs and save lives in developing economies.

    In a ruling that went to the heart of patent law in a country known as the "pharmacy to the world", the top court said Glivec - often hailed as a "silver bullet" for its breakthrough in treating a deadly form of leukemia - "did not satisfy the test of novelty or inventiveness" required by Indian legislation.

    The court's decision has global significance since India's $26 billion generic drug industry, which supplies much of the cheap medicine used in the developing world, could be stunted if Indian law allowed global drug companies to extend the lifespan of patents by making minor changes to medicines.

    Once a drug's patent expires, generic manufacturers can legally produce it. They are able to make drugs at a fraction of the original manufacturer's cost because they don't carry out the expensive research and development.

    The case is the highest profile one of several battles being waged in India. It is seen as having far-reaching implications in defining the extent of patent protection for multinational drug firms operating in the lucrative market.

    "The ruling has come as a big relief," Leena Menghaney, a lawyer with medical charity Medecins Sans Frontieres, said outside the courtroom. "It will save a lot of lives - not only in India, but across the developing world.

    Novartis, which reported net profit of $9.6 billion in 2012 on sales of $56.7 billion, condemned the judgment, saying in a statement it "discourages innovative drug discovery essential to advancing medical science for patients".

    Ranjit Shahani, managing director of Novartis India, said, "This ruling is a setback for patients that will hinder medical progress for diseases without effective treatment options."

    Pratibha Singh, a lawyer for the Indian generic drug manufacturer Cipla, which makes a version of Glivec for less than a tenth of the original drug's selling price, said the court ruled that a patent could only be given to a new drug, and not to those which are only slightly different from the original.

    "Patents will be given only for genuine inventions, and repetitive patents will not be given for minor tweaks to an existing drug," Singh said outside the court.

    Novartis has fought a legal battle in India since 2006 to patent a new version of Glivec, known as Gleevec outside India and Europe. Novartis said Glivec is patented in nearly 40 other countries, including China, the United States and Russia.

    Anand Grover, a lawyer for the Cancer Patients Aid Association, which led the legal fight against Novartis, said the ruling on Monday prevents the watering down of India's patent laws.

    "This is a very good day for cancer patients. It's the news we have been waiting for seven long years," he said.

    Medecins Sans Frontieres said Glivec costs $4,000 a month in its branded form, while the generic version is available in India for around $73.

    "The difference in price is huge. The generic version makes it affordable to so many more poor people, not just in India, but across the world," said Y. K. Sapru, of the Mumbai-based cancer patients association.

    AP-AFP-Reuters

    (China Daily 04/02/2013 page12)

    Today's Top News

    Editor's picks

    Most Viewed

    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    无码人妻精品一区二区三区99性 | 小泽玛丽无码视频一区| 久久久久亚洲AV片无码下载蜜桃| 久久人妻少妇嫩草AV无码蜜桃| 中文字幕一区二区三区乱码| 中文字幕人成高清视频| 久久久久亚洲av无码专区喷水 | 一区二区三区在线观看中文字幕| 亚洲av无码乱码在线观看野外| 午夜亚洲AV日韩AV无码大全| 中文字幕人妻在线视频不卡乱码 | 精品人妻无码专区中文字幕| 亚洲乱亚洲乱少妇无码| 国产成人无码综合亚洲日韩| 亚洲国产综合无码一区| 国产成人无码AV麻豆| 亚洲第一中文字幕| 亚洲.欧美.中文字幕在线观看| 国产精品无码永久免费888| 日韩免费无码视频一区二区三区| 精品亚洲成A人无码成A在线观看| 日本精品久久久中文字幕| 亚洲一区无码精品色| 2021国产毛片无码视频| 蜜桃臀无码内射一区二区三区| 亚洲成AV人在线观看天堂无码| 久久久无码精品亚洲日韩京东传媒| 国产中文字幕在线免费观看| 中文国产成人精品久久不卡| 伊人蕉久中文字幕无码专区| 一本大道久久东京热无码AV| 亚洲Av无码乱码在线播放| 成人无码小视频在线观看| 国产成人精品无码片区在线观看| 玖玖资源站无码专区| 超清无码一区二区三区| 国产AV无码专区亚洲AV男同| 国产∨亚洲V天堂无码久久久| 国产日韩精品无码区免费专区国产 | 日韩免费无码一区二区三区| 久久精品中文无码资源站|